Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE – Get a rating) received a consensus “moderate buy” recommendation from the twelve brokerages that currently cover the stock, reports MarketBeat Ratings. One investment analyst gave the stock a sell rating, one gave the company a hold rating and five gave the company a buy rating. The 12-month average price target among brokers who updated their coverage on the stock in the past year is $112.09.
A number of brokerages have recently commented on RARE. Barclays lowered its price target on Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday, July 29 research report. Piper Sandler lowered her price target on Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating on the stock in a Thursday, July 28 research report. Stifel Nicolaus lowered his price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating on the stock in a research report on Friday July 1. StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a Tuesday, June 21 research report. Finally, Citigroup lowered its price target on Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, August 3 research report.
Ultragenyx pharmaceutical stock down 1.5%
RARE opened at $39.94 on Friday. Ultragenyx Pharmaceutical has a 52 week low of $39.55 and a 52 week high of $89.56. The company has a market capitalization of $2.80 billion, a P/E ratio of -5.46 and a beta of 1.24. The company’s 50-day moving average price is $47.54 and its 200-day moving average price is $56.92.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last released its results on Thursday, July 28. The biopharmaceutical company reported ($2.26) EPS for the quarter, missing analyst consensus estimates of ($1.72) by ($0.54). The company posted revenue of $89.34 million in the quarter, compared to $87.33 million expected by analysts. Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. Ultragenyx Pharmaceutical’s quarterly revenue increased 2.7% year-over-year. In the same quarter of the previous year, the company achieved EPS of ($1.45). On average, research analysts expect Ultragenyx Pharmaceutical to post an EPS of -8.45 for the current fiscal year.
Institutional entries and exits
Major investors have recently changed their positions in the company. IndexIQ Advisors LLC acquired a new position in shares of Ultragenyx Pharmaceutical during Q1 worth approximately $44,000. Lazard Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company worth $64,000 after purchasing an additional 240 shares during the period. Harbor Capital Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during Q1 worth approximately $169,000. Essex Investment Management Co. LLC increased its stake in shares of Ultragenyx Pharmaceutical by 14.9% during the 1st quarter. Essex Investment Management Co. LLC now owns 2,682 shares of the biopharmaceutical company worth $195,000 after buying 348 additional shares during the period. Finally, Alta Wealth Advisors LLC acquired a new position in shares of Ultragenyx Pharmaceutical during Q1 worth approximately $218,000. 88.27% of the shares are held by institutional investors and hedge funds.
About Ultranyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here